$348.24
0.64% today
NYSE, Feb 05, 04:04 pm CET
ISIN
US0905721082
Symbol
BIO
Sector

Bio-Rad Laboratories, Inc. Class B Stock price

$346.03
+2.56 0.75% 1M
+17.35 5.28% 6M
+17.52 5.33% YTD
+27.31 8.57% 1Y
-280.66 44.78% 3Y
-17.69 4.86% 5Y
+229.22 196.23% 10Y
NYSE, Closing price Tue, Feb 04 2025
-7.08 2.01%
ISIN
US0905721082
Symbol
BIO
Sector

Key metrics

Market capitalization $9.69b
Enterprise Value $9.45b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 38.31
EV/Sales (TTM) EV/Sales 3.66
P/S ratio (TTM) P/S ratio 3.75
P/B ratio (TTM) P/B ratio 1.29
Revenue growth (TTM) Revenue growth -5.15%
Revenue (TTM) Revenue $2.58b
EBIT (operating result TTM) EBIT $344.46m
Free Cash Flow (TTM) Free Cash Flow $246.55m
Cash position $1.63b
EPS (TTM) EPS $-27.33
P/S forward 3.76
EV/Sales forward 3.66
Short interest 3.82%
Show more

Is Bio-Rad Laboratories, Inc. Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Bio-Rad Laboratories, Inc. Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Bio-Rad Laboratories, Inc. Class B forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Bio-Rad Laboratories, Inc. Class B forecast:

Buy
75%
Hold
25%

Financial data from Bio-Rad Laboratories, Inc. Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,580 2,580
5% 5%
100%
- Direct Costs 1,176 1,176
7% 7%
46%
1,404 1,404
4% 4%
54%
- Selling and Administrative Expenses 616 616
2% 2%
24%
- Research and Development Expense 247 247
7% 7%
10%
541 541
10% 10%
21%
- Depreciation and Amortization 197 197
2% 2%
8%
EBIT (Operating Income) EBIT 344 344
13% 13%
13%
Net Profit -779 -779
389% 389%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Rad Laboratories, Inc. Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Rad Laboratories, Inc. Class B Stock News

Neutral
Business Wire
9 days ago
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time...
Neutral
Business Wire
28 days ago
ST. LOUIS & HERCULES, Calif.--(BUSINESS WIRE)--Geneoscopy raises $105 million in Series C funding round, led by Bio-Rad Laboratories.
Neutral
Business Wire
about one month ago
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morg...
More Bio-Rad Laboratories, Inc. Class B News

Company Profile

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Head office United States
CEO Norman Schwartz
Employees 8,030
Founded 1952
Website www.bio-rad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today